Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.
I'm PortAI, I can summarize articles.
Sarepta Therapeutics Inc. received positive news from the FDA, allowing the resumption of shipments for its DMD drug, Elevidys, after a pause due to safety concerns. The FDA confirmed that one patient death was unrelated to the drug. Despite a 17.4% stock increase, analysts express caution about restoring confidence among doctors and patients. J.P. Morgan upgraded the stock to neutral, while Oppenheimer turned bullish, acknowledging challenges ahead. The stock has seen a significant decline of 88.9% in 2025, contrasting with gains in the broader biotech sector.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments